TABLE 2.
Relative sensitivities of SIV variants containing amino acid substitutions in the potential O-linked glycosylation site to neutralization of infectivity by SIVmac239-positive rhesus macaque sera, soluble CD4, or a panel of rhesus monoclonal antibodiesa
| Viral strain | Potential O-linked sequence (aa 128-139) | Serum IC50 (inverse dilution) | sCD4 IC80 (μg/ml) | rhMAb IC50 (μg/ml) |
|---|---|---|---|---|
| SIVmac239 | TTTASTTSTTAS | <80 | 3 | >10 |
| SIV316 | TTTASTTSTTAS | >10,240 | 0.05 | >10 to <0.078 |
| Jacalin1 | TTTASTT---AS | <80 | 1.75 | >10 |
| Jacalin2 | TTTASTTSMTAS | <80 | 3 | >10 |
| Jacalin3 | TTTASTTSGTAS | <80 | 3 | >10 |
| Jacalin4 | ITAASTTSMTAS | <80 | 1.75 | >10 |
| Jacalin5 | GTGASTTSGTAS | 120 | 3 | >10 |
| Jacalin6 | TATASTTSMTAS | <80 | 3 | >10 |
| Jacalin7 | TTAASTTSMTAS | <80 | 3 | >10 |
| Jacalin8 | TTIASTTSMTAS | <80 | 3 | >10 |
| SIV04 | VVVAAVTSTTAS | <80 | 2 | >10 |
| SIV05 | TTTASTVAVVAA | 300 | 1.75 | >10 |
| SIV06 | TVTAAVTAVTAA | 400 | 2 | >10 |
| SIV07 | VAVASVAAVVAS | 2,560 | 1.75 | >10 |
a
sCD4, soluble CD4; rhMAb, rhesus monoclonal antibodies.